NEXLETOLNEXLETOL is similar to NEXLIZET in its FDA indication as an adjunct to diet and statin therapy to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional help lowering of LDL cholesterol.

In September, NEXLETOL began a direct-to-consumer campaign advertising the potential of the drug to support LDL cholesterol lowering as an adjunct to diet, exercise and statin treatment.